Skip to Main Content

Author Details

Mariaelena Pierobon
Center for Applied Proteomics and Molecular Medicine, George Mason University
2004
77
27
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36797347AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.NPJ Precis Oncol2023
37707814Geographical Variation in Social Determinants of Female Breast Cancer Mortality Across US Counties.JAMA Netw Open2023
37902050Functional proteomic analysis, a missing piece for understanding clonal evolution and cooperation in the tissue microecology.Expert Rev Mol Diagn2023
37370621Automated Classification of Lung Cancer Subtypes Using Deep Learning and CT-Scan Based Radiomic Analysis.Bioengineering (Basel)2023
34635507Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway.Mol Cancer Res2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
36046628Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach.Cell Rep Methods2022
36069770Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.Elife2022
35944066Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutations.Sci Signal2022
34921013Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.Cancer Res2022
35247914Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.Mol Cancer Ther2022
34437759Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.Mol Oncol2022
33320980Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.Mol Oncol2021
33802212Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models.Int J Mol Sci2021
34852220CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.Cell Rep2021
34573384Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.Genes (Basel)2021
34688654The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.J Biol Chem2021
34620701PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.J Immunother Cancer2021
34154611Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN.J Exp Clin Cancer Res2021
34278265Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.iScience2021
31433055Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.Neuro Oncol2020
31658955The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov2020
31649109Atypical KRAS<sup>G12R</sup> Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.Cancer Discov2020
32553168Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Cell Rep2020
32165870The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow.Clin Proteomics2020
32483362Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nat Med2020
31164413The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.Mol Cancer Res2019
31698248Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.iScience2019
31268978Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis.Pancreas2019
31209845Utilization of Proteomic Technologies for Precision Oncology Applications.Cancer Treat Res2019
30833752Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.Nat Med2019
28802252Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.Mol Cancer Ther2018
30205811An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.BMC Med2018
30301389Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.Expert Rev Proteomics2018
28765579Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.Sci Rep2017
28159918Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.Oncotarget2017
28446508Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.Clin Cancer Res2017
28502000Reverse Phase Protein Microarrays.Methods Mol Biol2017
29137348Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.Oncotarget2017
28651964Protein network construction using reverse phase protein array data.Methods2017
28664915Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.Br J Cancer2017
26725216Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Cancer Cell2016
27825696A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.Mol Oncol2016
26915507Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response.Ecohealth2016
24608425Application of molecular technologies for phosphoproteomic analysis of clinical samples.Oncogene2015
26576427Phosphorylation, Signaling, and Cancer: Targets and Targeting.Biomed Res Int2015
26392102Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.J Clin Oncol2015
26468985Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Oncotarget2015
25676683Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.Proteomics Clin Appl2015
25802059Lung cancer prognosis before and after recurrence in a population-based setting.J Natl Cancer Inst2015
  • 1 - 50 of 77

Recommended Authors

Rehan Akbani
The University of Texas MD Anderson Cancer Center
Career Start Year 2013
Number of shared co-authors 4
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Kris Ylaya
Center for Cancer Research, National Cancer Institute
Career Start Year 2008
Number of shared co-authors 3
Karolina Edlund
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 0
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Nicholas A Graham
University of Southern California
Career Start Year 2004
Number of shared co-authors 0
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 3
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 2
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 0
Tamar Geiger
Tel Aviv University
Career Start Year 2000
Number of shared co-authors 0
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 3
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 3
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 1
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 1
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Donald J Johann
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences
Career Start Year 1996
Number of shared co-authors 3
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 7
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 7
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 3
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 1
Stephen M Hewitt
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 8
David L Rimm
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 11

Collaborators

Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 62
Lance A Liotta
Co-authored papers 31
Giuseppe Giaccone
Meyer Cancer Center
Co-authored papers 4
Krister Wennerberg
University of Copenhagen
Co-authored papers 4
Elisa Pin
KTH Royal Institute of Technology
Co-authored papers 4
Kris C Wood
Duke University
Co-authored papers 3
Costas A Lyssiotis
Co-authored papers 3
John D Carpten
Co-authored papers 3
Kevin H Lin
Duke University
Co-authored papers 2
Thomas P Conrads
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 2
George L Maxwell
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 2
Laura E Herring
Co-authored papers 2
David W Craig
University of Southern California
Co-authored papers 2
Ancha Baranova
Co-authored papers 2
Bhaskar Kallakury
Georgetown University
Co-authored papers 2
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Co-authored papers 2
Jann N Sarkaria
Co-authored papers 1
Massimo Cristofanilli
Weill Cornell School of Medicine
Co-authored papers 1
Sara A Byron
Co-authored papers 1
Myles Brown
Co-authored papers 1
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Melissa Rotunno
Boston Children's Hospital and Harvard Medical School
Co-authored papers 1
Margaret A Tucker
National Cancer Institute
Co-authored papers 1
Camille Vaganay
Universite de Paris, INSERM, CNRS
Co-authored papers 1
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 1
David A Rizzieri
Duke University Medical Center
Co-authored papers 1
Timothy J Triche
Center for Epigenetics, Van Andel Research Institute
Co-authored papers 1
Niven Mehra
Radboud university medical center
Co-authored papers 1
Xinghai Li
Duke University
Co-authored papers 1
Sholom Wacholder
National Cancer Institute
Co-authored papers 1
Release 1.2